Advanced in Nonalcoholic Steatohepatitis (NASH)

Dr. Mark T. Leibowitz

Internal Medicine
2600 Redondo Ave, Suite 500, 
Long Beach, CA 
Advanced in Nonalcoholic Steatohepatitis (NASH)
2600 Redondo Ave, Suite 500, 
Long Beach, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Leibowitz is a primary care provider, practicing in Internal Medicine in Long Beach, California. Dr. Leibowitz is rated as an Advanced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Type 2 Diabetes (T2D).

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 2 clinical trials in the study of Nonalcoholic Steatohepatitis (NASH).

Specialties
Internal Medicine
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

2600 Redondo Ave, Suite 500, Long Beach, CA 90806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test
Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test
Enrollment Status: Completed
Publish Date: January 11, 2021
Intervention Type: Device
View 8 Less Clinical Trials

4 Total Publications

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 04, 2022
Similar Doctors
Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Dong H. Lee
Geriatrics | Internal Medicine
Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Dong H. Lee
Geriatrics | Internal Medicine
2727 W Olympic Blvd Ste 309, 
Los Angeles, CA 
 (19.0 miles away)
213-674-7758
Languages Spoken:
English
See accepted insurances

Dong Lee is a primary care provider, practicing in Geriatrics and Internal Medicine in Los Angeles, California. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Hepatitis, Vitrectomy, and Osteotomy.

Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Narsis K. Moshfeghi
Internal Medicine
Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Narsis K. Moshfeghi
Internal Medicine
7325 Medical Ctr Dr, Suite 306, 
West Hills, CA 
 (38.9 miles away)
818-703-7027
Languages Spoken:
English
See accepted insurances

Narsis Moshfeghi is a primary care provider, practicing in Internal Medicine in West Hills, California. Dr. Moshfeghi is rated as a Distinguished provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). Her top areas of expertise are Degos Disease, Sitosterolemia, Anemia, and Homocystinuria due to MTHFR Deficiency.

Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Courtney L. Hanlon
Internal Medicine
Advanced in Nonalcoholic Steatohepatitis (NASH)
Dr. Courtney L. Hanlon
Internal Medicine
1200 N State Street, Clinic Tower, Suite A7d, 
Los Angeles, CA 
 (17.8 miles away)
323-409-7556
Languages Spoken:
English
See accepted insurances

Courtney Hanlon is a primary care provider, practicing in Internal Medicine in Los Angeles, California. Dr. Hanlon is rated as an Experienced provider by MediFind in the treatment of Nonalcoholic Steatohepatitis (NASH). Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Neurosyphilis, Primary Biliary Cholangitis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leibowitz's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile